Cubist sales force seen as potential boon for Merck intestinal drug

December 9, 2014 11:54 PM

15 0

(Reuters) - In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients.

Merck announced on Monday an agreement to buy Cubist for $8.4 billion, with a focus on Cubist's drugs that address the growing threat of bacteria that are resistant to conventional antibiotics. [ID:nL3N0TS3VA]

Read more

To category page